Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 7/20 | 0.46 |
| ▸ | LCK | P06239 | 11/20 | 0.43 |
| ▸ | IL1B | P01584 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6626815 | 0.81 | CASP1 (0.45) | CASP1LCKIL1BMMEACE | |
| SCHEMBL6629248 | 0.78 | CASP1 (0.42) | CASP1LCKIL1BMMEACE | |
| SCHEMBL6626933 | 0.78 | LCK (0.54) | CASP1LCKMMEACE | |
| SCHEMBL6626934 | 0.78 | LCK (0.54) | CASP1LCKMMEACE | |
| SCHEMBL6626636 | 0.77 | LCK (0.53) | CASP1LCKMMEACE | |
| SCHEMBL6628293 | 0.75 | LCK (0.51) | CASP1LCKIL1BMMEACE | |
| SCHEMBL6631022 | 0.75 | LCK (0.51) | CASP1LCKIL1BMMEACE | |
| SCHEMBL6627256 | 0.73 | CASP1 (0.48) | CASP1LCKIL1BMMEACE | |
| SCHEMBL6627258 | 0.73 | CASP1 (0.48) | CASP1LCKIL1BMMEACE | |
| SCHEMBL6628142 | 0.72 | CASP1 (0.48) | CASP1LCKIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246824-B1 | CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2004-06-09 | — | — | EP | claimed |
| US-20030100550-A1 | Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof | AVENTIS PHARMA S.A. (FR) | 2003-05-29 | — | — | US | claimed |
| EP-1246824-B1 | CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2004-06-09 | — | — | EP | disclosed |
| US-20030100550-A1 | Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof | AVENTIS PHARMA S.A. (FR) | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100550-A1 | Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof | HRH4, HRH3, HRH2 | CASP1 2506/4885LCK 4642/4885IL1B 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.